Ultomiris Drug Market Overview: Growth, Trends, and Future Projections
The Ultomiris drug market is experiencing robust expansion, driven by rising demand for advanced treatments in rare complement-mediated disorders. Ultomiris (ravulizumab-cwvz), a long-acting C5 complement inhibitor developed by Alexion Pharmaceuticals (now a subsidiary of AstraZeneca), has emerged as a...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek